Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Elicio Therapeutics, Inc. (ANGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
SC 13G/A
| Vifor Ltd reports a 0% stake in Elicio Therapeutics, Inc. |
| 06/12/2023 |
SC 13D
| Clal Biotechnology Industries Ltd. reports a 7.1% stake in Elicio Therapeutics, Inc. |
| 06/02/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Material Modifications to Rights of Security Holders, Changes in Registra...|
Docs:
|
"Certificate of Merger",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement the Reverse Stock Split",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement Officer Exculpation",
"Certificate of Amendment, to the Amended and Restated Certificate of Incorporation of Angion Biomedica Corp. to implement the name change",
"Suite 501 Boston, MA 02210",
"Form of Indemnification Agreement between the Company and each of its directions and officers",
"Information Rights Letter, by and between Clal Biotechnology Industries Ltd. and Elicio Therapeutics, Inc",
"Letter from Moss Adams LLP",
"NEWTON, Massachusetts, June 1, 2023 ––",
"Elicio Therapeutics Announces Completion of Merger with Angion Biomedica" |
|
| 05/30/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/30/2023 |
8-K
| Other Events Interactive Data |
| 05/23/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/23/2023 |
8-K
| Other Events Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/01/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/21/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 04/13/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 03/29/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 03/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| EISA-ABC LLC reports a 5.7% stake in Angion Biomedica Corp. |
| 02/13/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/18/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/17/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/17/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/17/2023 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among Angion Biomedica Corp., Arkham Merger Sub, Inc. and Elicio Therapeutics, Inc",
"Note Purchase Agreement, by and between Elicio Therapeutics, Inc. and Angion Biomedica Corp., and Form of Promissory Note",
"Form of Angion Biomedica Corp. Stockholder Support Agreement",
"Form of Elicio Therapeutics, Inc. Stockholder Support Agreement",
"Form of Lock-Up Agreement",
"No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended." |
|
| 12/21/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
8-K
| Quarterly results |
|
|
|